AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00731042
Drug: Purell Surgical Scrub
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical solution, 4 mL, 6 applications/day for 14 days.
Trial: NCT01038063
Drug: Artemether-lumefantrine combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03248297
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin tablet
Trial: NCT03248297
Drug: Azithromycin and amoxicillin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin and amoxicillin
Trial: NCT03248297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT01267279
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid per protocol
Trial: NCT03530293
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-active dosage form
Trial: NCT00687934
Drug: STA-9090
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 (ganetespib)during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 (gantespib) provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.
Trial: NCT03952065
Drug: PD1/PDL1/CTLA4 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of PD1/PDL1/CTLA4 inhibitors through peripheral vein or neck artery/intra-tumor.
Trial: NCT04071080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mL Gatorade
Trial: NCT01216033
Drug: 111-In-ABY-025
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of the agent
Trial: NCT00244231
Drug: Nidadd
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00354393
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01886820
Drug: [18F]NAV4694
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01427387
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02991885
Drug: HAL-MPE1 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous administrations of HAL-MPE1 placebo
Trial: NCT03134157
Drug: oral drug and vaginal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prescription of simvastatin 40 mg orally+ vaginal placebo every day for 3 months.
Trial: NCT03134157
Drug: oral drug and oral placebo
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prescription of simvastatin 40 mg orally+ oral placebo every day for 3 months.
Trial: NCT03134157
Drug: Vaginal placebo+ oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prescription of Vaginal placebo + oral placebo every day for 3 months.
Trial: NCT04259333
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib tablet
Trial: NCT00523211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of placebo once daily.
Trial: NCT04259333
Drug: Acetaminophen, Codeine Drug Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen-codeine-caffeine tablet
Trial: NCT01561209
Drug: Amitryptiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitryptiline 5 mg before bedtime for 2 months
Trial: NCT01561209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill~1 before bedtime
Trial: NCT02529813
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03688295
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive antiobitherapy post surgery for CAA
Trial: NCT01277861
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FENTANYL PRETREATMENT DURING INDUCTION OF ANESTHESIA
Trial: NCT03285178
Drug: IW-1701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT02239211
Drug: BTT1023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV (in the vein) Investigational Medicinal Product (IMP)
Trial: NCT03285178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT03324685
Drug: BIIB074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB074 is administered as specified in the treatment arm.
Trial: NCT03324685
Drug: OC (ethinyl estradiol and levonorgestrel)
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC is administered as specified in the treatment arm.
Trial: NCT01416038
Drug: low dose cyclophosphamide (oral)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cyclophosphamide will be taken by mouth.
Trial: NCT02016846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03609853
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vapor (distilled water)
Trial: NCT03609853
Drug: Vaporized THC, limonene, or THC and limonene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute drug exposure
Trial: NCT01340820
Drug: AERAS-422
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rBCG
Trial: NCT01340820
Drug: BCG Tice
RxNorm normalized name: BCG TICE 50MG/AMP VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-8 x 10\^5 CFU
Trial: NCT03645603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion of physiological saline solution to mimic dexmedetomidine infusion
Trial: NCT01084161
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV placebo once per day
Trial: NCT02265510
Drug: INCB039110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB039110 tablets administered orally at the protocol specified dose strength and frequency.
Trial: NCT02340455
Drug: Placebo_Men
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo durg
Trial: NCT02340455
Drug: Placebo_Women
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo_Women
Trial: NCT01357772
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02763098
Drug: Remi 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.1 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
Trial: NCT02763098
Drug: Remi 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: .Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.2 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
Trial: NCT02915835
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID;
Trial: NCT02763098
Drug: Remi 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.3 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
Trial: NCT05732948
Drug: autologous T cells & cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of PD-1(programmed death 1)silent PSMA(prostate-specific membrane antigen)/PSCA(prostate stem cell antigen)targeted CAR-T administered one day after pretreatment with cyclophosphamide.
Trial: NCT00523042
Drug: inhaled human insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target dose titration scheme, inhalation.
Trial: NCT02623153
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine of 1000 mg/m2
Trial: NCT03630341
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets identical to L-carnitine
Trial: NCT01293461
Drug: CBX129801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT01293461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT01660126
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg.
Trial: NCT01660126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02147353
Drug: Cryotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy will be standardized in all subjects and for all treated lesions.
Trial: NCT02745392
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)
Trial: NCT02949960
Drug: DMT210 Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMT210 Topical Aqueous Gel 5% applied twice daily
Trial: NCT02045966
Drug: Cocktail
RxNorm normalized name: Cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg
Trial: NCT02045966
Drug: DCV 3DAA FDC
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCV 30 mg + ASV 200 mg + BMS-791325 75 mg
Trial: NCT01033643
Drug: MK-3614
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were administered 0.25 mg tablet, orally for a total daily dose according to randomization.
Trial: NCT01033643
Drug: Placebo for MK-3614
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were administered dose matched placebo tablets according to randomization.
Trial: NCT02823743
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intake
Trial: NCT00116142
Drug: Androgen Suppression Therapy and Radiation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Androgen Ablation and External Beam Radiation Therapy
Trial: NCT03840239
Drug: Capecitabine, Oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Capecitabine, Oxaliplatin
Trial: NCT00892723
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
Trial: NCT00892723
Drug: AZX100 Drug Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
Trial: NCT03599960
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Idarubicin 12mg/m2 IV at D1~* Methotrexate at D1 (24H infusion, alkaline hydration, leucovorin rescue):~  * Patients \<65y and albuminemia \>35 g/l and CrCl (MDRD)\>60 ml/min: 3000 mg/m²~ * Patients \<65y and albuminemia \<35 g/l and/or CrCl (MDRD) \<60 ml/min: 1000 mg/m² IV~ * Patients ≥65y and albuminemia \>35 g/l and CrCl (MDRD) \> 60 ml/min : 1000 mg/m²~ * Patients ≥ 65y and albuminemia \< 35 g/l and/or CrCl (MDRD) \< 60 ml/min : 500 mg/m²~* L-asparaginase (SPECTRILA) : 5000 units/m² IV at D2, 5, 8, 11 (switch to Erwinia asparaginase/Cirsantaspase 25 000 U/m² with the same drug regimen in case of hypersensitivity reactions or significant diminution of asparaginase activity)~* Dexamethasone 40mg PO or IV at D1-4 (dose diminution at 20 mg for Age ≥65y)
Trial: NCT00426153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
Trial: NCT03507790
Drug: CT1812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Study Drug
Trial: NCT03507790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active study drug
Trial: NCT04854668
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 850mg/m2 administrated orally twice daily from Day 1-14.
Trial: NCT01313689
Drug: Physicians' Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ofatumumab containing regimen as per physicians' choice for up to 6 months. Permitted therapies include treatments approved for CLL, and well established standards of care for CLL.
Trial: NCT01421771
Drug: Antihypertensive Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study formulary consists of ACE/ARB, Beta Adrenergic Blocker, Calcium Channel Blocker, vasodilators, peripheral alpha antagonist and central alpha agonist.~ACE I or ARB is first line, the order of addition of subsequent medications is per the discretion of the investigator
Trial: NCT00125918
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet taken by mouth once a day for 16 weeks
Trial: NCT04005872
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide is a gold standard for indirect pulp capping which induces hard tissue.
Trial: NCT04186156
Drug: KA2507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
Trial: NCT03422978
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose normal saline administered over 60 seconds post-induction.
Trial: NCT02181959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02402972
Drug: oxaliplatin+Leucovorin+5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy: oxaliplatin+Leucovorin+5-FU
Trial: NCT00887432
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04160767
Drug: Probiotic Vivomixx
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIVOMIXX once a day for 4 months. VIVOMIXX® is a probiotic containing 8 differenct strains of bacteria: Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734). Every sachet contains 450 billions of bacteria, maltose and silicon dioxide. VIVOMIXX® will be freely given by the society MENDES S.A. - Lugano Switzerland.
Trial: NCT00629512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01026493
Drug: ABT-888 20 mg x 21 days
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg bid x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
Trial: NCT01026493
Drug: ABT-888 40 mg x 21 days
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy
Trial: NCT01026493
Drug: ABT-888 40 mg x 5 days
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg bid x 5 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
Trial: NCT04655313
Drug: ARQ-151 cream 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
Trial: NCT00743405
Drug: GSK1034702
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or liquid
Trial: NCT00743405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To match GSK1034702
Trial: NCT00451698
Drug: acyanotic placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose IV push
Trial: NCT05002179
Drug: Echinaforce Chewable tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment: 3X2 EC tablets daily during 2 + 2 months of prevention after run-in of 1 week and intermittent treatment break of 1 week without treatment + 1 month of voluntary follow-up prevention.~Acute treatment: 5 X 2 EC tablets daily for max. 10 days per individual vRTI or until symptom resolution.
Trial: NCT01209676
Drug: IMCgp100 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a monoclonal T cell receptor anti-CD3scFv fusion protein
Trial: NCT01445756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; no topical lidocaine administered
Trial: NCT04408183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is given as a nasal spray using an atomizer
Trial: NCT03369990
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT00551460
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00551460
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01014260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a randomized double-blind clinical trial of doxycycline 20 mg bid versus 100mg bid versus placebo, given for 3 months, to be conducted at a single center (JHH).
Trial: NCT01014260
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 20 mg bid versus Doxycycline 100 mg bid versus placebo
Trial: NCT02803892
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 will be titrated according to a random schedule alternating plausible doses of placebo. After 4 weeks of treatment patients will discontinue placebo 1